Hamadan University of Medical Sciences and Health Services (UMSHA) is a medical school in Iran. Located in the city of Hamadan. Hamadan University of Medical Sciences was founded in March 1972 as a joint program between Iran and France under the name of the Bouali Sina University.In 1986, the present university was established under the supervision of the ministry of Health. In 1993, Health and Treatment Organization joined to the Medical University and covered all Health, treatment, education, research, development and human resource affairs under a same authority and make this university the main provider of health services in the province.Hamadan University of Medical Sciences is among "top 10 medical universities of Iran" offering more than 70 degree programs and 21 non-degree training programs. In 2013, UMSHA was introduced as a type A (highest quality of education and research) Medical university in Iran.According to the report extracted from the Basic Indicators of Science (ESI) database, at the end of 2018, Hamadan University of Medical Sciences was among the top one percent of universities and research institutes in the world. University is one of the quick growing universities in the world.UMSHA has 8 faculties, operates 16 hospitals plus rural and urban health care centers. Hamadan University of Medical Sciences currently has 6339 students in more than seventy undergraduate and graduate programs, including Associate degrees, Bachelor of Sciences, Masters, PhD and the Specialties programs. There are 445 academic members. This university is established in an educational area of 44241 square meters with a standard campus in the beautiful hillside of Alvand Mountain and the honored city of Avicenna.University DeansMore information Chairman's name, date of appointment ...Name of the Chairman Date of appointmentDr. Mohammad Ebrahim Shadmani 1976Dr. Houshang Tarzi 1978Dr. Mahmoud Tehrani 1986Dr. Abbas Moeini 1986Dr. Soleimani Asl 1/10/66Dr. Ahmad Ameri 14/9/68Dr. Farid Abolhassani Shahreza 4/5/73Dr. Seyed Hamid Hashemi 16/4/77Dr. Abbas Zamanian 9/12/79Dr. Aref Salehi 8/20/81Dr. Abdullah Farhadi Nasab 2/12/84Dr. Reza Safi Arian 7/19/88Dr. Habibaullah Mousavi Spring 2/29/92Dr.
INTRODUCTION:Low back pain (LBP) is a well-recognized and major cause of disability worldwide. This study aimed to compare the effects of dynamic neuromuscular stabilization (DNS) exercises with and without the Feldenkrais method (FM) on pain, balance, and hip muscle strength in elderly women with chronic non-specific LBP (CNLBP). METHOD:In this randomized controlled trial, 40 women aged 60-80 years with CNLBP were randomly allocated to either the DNS exercise (DNSE) group or the combined DNS and Feldenkrais method exercise (DNS-FME) group for an 8-week intervention. Three participants dropped out, leaving 37 completers (18 in the DNSE group and 19 in the DNS-FME group). Baseline and post-intervention assessments were conducted 1-3 days before the first session and 1-3 days after the final session, respectively. Outcome measures included pain intensity, Berg Balance Scale score, and hip muscle strength. Data were analyzed using repeated-measures ANOVA, with statistical significance set (p < 0.05). RESULTS:After the 8-week intervention, significant group-by-time interactions were observed for all outcome variables (p < 0.05). Post-hoc analysis with Bonferroni correction revealed that the DNS-FME group exhibited significantly greater reductions in pain intensity (p < 0.001) as well as significantly greater improvements in hip adductor strength (p < 0.001) and hip abductor strength (p < 0.001) compared to the DNSE group. Although balance improvements were noted in both groups, the between-group difference did not reach statistical significance. CONCLUSION:The addition of the Feldenkrais method to dynamic neuromuscular stabilization exercises provides superior benefits in pain reduction and hip muscle strengthening in elderly women with chronic non-specific low back pain. Both interventions improve balance, but combined training may offer greater clinical advantages. These findings support integrating sensorimotor awareness techniques into rehabilitation programs for older adults with low back pain.
ABSTRACT:This systematic review summarizes the evidence informing 2 recommendations from the updated American Society of Hematology guidelines for the treatment of newly diagnosed acute myeloid leukemia in older adults, comparing conventional induction and postremission therapy vs hypomethylating agents (HMA)- or low-dose cytarabine (LDAC)-based strategies, with or without venetoclax. We searched Ovid MEDLINE and Embase, and Cochrane CENTRAL through February 2024, and monitored these databases for new studies throughout November 2024. We included randomized controlled trials (RCTs) and nonrandomized studies (NRS). Reviewers screened studies, extracted data, assessed risk of bias, conducted random-effects meta-analyses, and rated certainty of evidence using GRADE (grading of recommendations, assessment, development, and evaluation). We included 21 studies (3 RCTs, 18 NRS). Compared with HMA- or LDAC-based monotherapy, conventional 7+3-type remission induction therapy may reduce mortality at longest follow-up (risk ratio [RR], 0.94; 95% confidence interval [CI], 0.85-1.04; low certainty), increase complete remission rates (odds ratio, 1.75; 95% CI, 1.25-2.38; high certainty), and may reduce recurrence at longest follow-up (RR, 0.81; 95% CI, 0.64-1.04; low certainty). Conventional therapies probably increase most severe toxicities (moderate certainty). Compared with HMA or LDAC combined with venetoclax, very low certainty evidence suggests that conventional therapy may reduce 1-year mortality (RR, 0.72; 95% CI, 0.60-0.87), increase allogeneic transplant rates (RR, 2.28; 95% CI, 1.70-3.06), result in no important differences in complete remission or recurrence, and have variable effects on severe toxicities. Conventional therapy may have benefits over HMA or LDAC alone; however, compared with HMA or LDAC plus venetoclax, the evidence remains of very low certainty.
Introduction: Childbirth is a physiological phenomenon that usually begins naturally with the spontaneous onset of pain in the 38-42 weeks of pregnancy and ends with the exit of pregnancy products. Spontaneous onset of labor and delivery is influenced by various factors such as changes in the level of estrogen, progesterone and prostaglandin hormones, changes in myometrial sensitivity to oxytocin and prostaglandins and the mutual effects of these factors. This study was conducted with aim to compare the effect of misoprostol and propranolol with misoprostol alone in induction of labor in mothers. Methods: This double-blind randomized clinical trial was conducted on 240 pregnant women referred to Kowsar Hospital during 2024. The data collection tool was a checklist including the patient's personal characteristics and clinical data. The control group was given 50 micrograms of sublingual misoprostol up two doses along with placebo, and the intervention group was given 50 micrograms sublingual misoprostol up to two doses and 20 mg propranolol tablets every 6 hours up to two doses. Induction with oxytocin was continued with the onset of uterine contractions. Data analysis was performed with SPSS (version 25) and Chi-square test and independent t-test. P<0.05 was considered statistically significant. Results: According to the results, there was no statistically significant difference between the two groups in terms of the number of pregnancies (p=0.676) and the Apgar score of the newborns (p=1.000). Moreover, the variables of hemoglobin before (p=0.959) and after (p=0.852) and its changes (p=0.842), systolic blood pressure (p=0.334) and diastolic blood pressure (p=0.484) did not have a statistically significant difference between the two groups. However, the mean of heart rate of the intervention group (85.18 ± 3.76) was significantly lower than that of the control group (86.22 ± 3.99) (P=0.040). In comparing the duration of labor phases, there was no statistically significant difference between the two groups in terms of latent phase (p=0.570), phase 1 (p=0.660), and phase 2 (p=0.704). Conclusion: Adding oral propranolol to misoprostol did not accelerate the duration of labor phases. Among the clinical variables, only the mean heart rate of the intervention group (85.18) was lower than that of the control group (86.22).
Guided endodontic access is increasingly used for severely calcified or obliterated canals, but most comparative evidence remains experimental and the extent to which technical advantages translate into clinical benefit is uncertain. This review evaluated the accuracy, efficiency, safety, and tooth-structure preservation of CBCT-based guided endodontic access. PubMed/MEDLINE, Scopus, Web of Science Core Collection, and Embase were searched from inception to 15 August 2026. Analytical clinical and experimental studies were distinguished from contextual clinical/safety reports. Static, dynamic, and robotic/haptic guidance were treated as separate intervention classes. Compatible outcomes were synthesized using outcome-appropriate meta-analytic methods, with HKSJ inference for few-study continuous random-effects analyses. Confidence in clinical inference was assessed using a GRADE-informed framework. Seventy-nine eligible reports were included: 32 reports representing independent analytical studies and 47 contextual clinical/safety reports. Twenty-five of the 32 analytical studies were non-clinical, and all primary meta-analyses concerned static guidance. Static guidance was associated with less tooth-structure loss (MD − 35.29 mm3, 95
A growing body of evidence implicates dysbiosis of the oral microbiome as a significant, modifiable risk factor for cardiovascular disease. This dysbiosis, often manifesting as periodontitis, initiates local inflammation and tissue destruction, however its systemic consequences are profound. Key mechanisms linking oral dysbiosis to cardiovascular disease involve the induction of endothelial dysfunction and chronic systemic inflammation. Pathogens and their virulence factors enter the bloodstream through inflamed periodontal tissues, directly impairing endothelial nitric oxide production and bioavailability, promoting vasoconstriction, leukocyte adhesion, and a pro-thrombotic state. Concurrently, microbial components activate innate immune receptors on endothelial and immune cells, triggering sustained release of pro-inflammatory cytokines and acute-phase proteins. The low-grade, systemic inflammation accelerates atherosclerosis by promoting foam cell formation, plaque instability, and vascular remodeling. Epidemiological studies consistently associate periodontitis with increased risks of myocardial infarction, stroke, and atherosclerosis severity, independent of traditional risk factors.